Regeneron expects $270 million from additional Ebola treatment supply through 2031
Key Facts
Regeneron expects to receive about $270 million under a new agreement with the U.S. Biomedical Advanced Research and Development Authority to supply additional doses of Inmazeb to the U.S. government through 2031. The company said the agreement expands a partnership that began when the agency purchased the treatment in 2020. The arrangement extends supplies of an approved treatment, while the evaluation of one of its components for use against Bundibugyo virus disease remains separate from the supply deal. Chief Executive Leonard Schleifer said, "Maintaining a ready stockpile of Inmazeb is exactly the kind of preparedness the country needs for threats we already see on the horizon." The company did not describe the $270 million as the total contract value, but said it was the amount it expects to receive under the new agreement.
Inmazeb is a combination of three antibodies: atoltivimab, maftivimab and odesivimab-ebgn. The U.S. Food and Drug Administration announced its approval on October 14, 2020, making it the first treatment approved for infection caused by Zaire ebolavirus in adults and children. The virus is referred to within the approved-use scope as Orthoebolavirus zairense. The FDA said approved treatments for this virus cannot be applied directly to outbreaks of Sudan ebolavirus or other types of Ebola viruses. This distinction defines the scope of the existing approval and does not automatically extend it to other strains.
In a clinical trial reviewed by the FDA, deaths within 28 days were 34% among Inmazeb recipients, or 52 of 154 patients. In the comparison group, which received the control treatment, the rate was 51%, or 78 deaths among 153 patients. Regeneron also says the treatment reduced deaths by about 55% compared with an active control treatment among patients with low viral loads. That result applies to the specific group identified by the company, while the FDA data show outcomes for the trial's two overall groups. The company said hundreds of patients have received Inmazeb since 2019.
The agreement comes as Bundibugyo virus disease is experiencing a major outbreak in the Democratic Republic of Congo. The World Health Organization said that as of October 20, 2026, 9,704 confirmed cases and 4,687 deaths had been recorded in eight provinces, with a crude fatality rate of 48.3%. In Kenya, nine cases, including one death, had been reported by the same date, while Nigeria confirmed an imported case. The organization said there are currently no licensed treatments or approved vaccines specifically for the prevention and treatment of Bundibugyo disease. Its advisory groups recommended limiting the use of candidate products for the disease to clinical trials, to generate evidence and support safe and ethical research.
Separately from the Inmazeb supply agreement, Regeneron is evaluating maftivimab as a potential treatment for Bundibugyo virus disease and says the experimental drug will be added to the PALM trial to study its use in the current outbreak. The company said maftivimab showed activity against the virus in laboratory studies and studies in nonhuman primates. The data are available in a preprint that has not yet undergone peer review. The University of Oxford's Pandemic Sciences Institute is coordinating the trial internationally, while the National Institute for Biomedical Research is leading the work nationally in the Democratic Republic of Congo. The World Health Organization is sponsoring the trial, with support from the Africa Centres for Disease Control and Prevention.
In trading, Regeneron shares closed at $805.02 on October 23, 2026, according to EL7 data. The data used here did not include the session's high or low price. In a separate measure from the company's contract, the U.S. Centers for Disease Control and Prevention said an order issued on October 11, 2026, restricts the entry of certain foreign nationals who had recently been in the Democratic Republic of Congo, Uganda or South Sudan. The order was set to take effect for 30 days from its issuance. The available information does not include a later date for delivery of the doses or a specific date for results from the PALM trial.